- Home
- BCSF vs AVTX Comparison
BCSF vs AVTX Comparison
Compare BCSF & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCSF | AVTX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 838.7M | 956.7M |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BCSF | AVTX |
|---|---|---|
| Price | $12.82 | $18.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $14.00 | ★ $40.57 |
| AVG Volume (30 Days) | 315.7K | ★ 1.9M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.61% | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $253.20 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $11.82 | $6.21 |
| 52 Week High | $15.84 | $24.27 |
Technical Indicators
Market Signals| Indicator | BCSF | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 55.10 |
| Support Level | $11.91 | $13.13 |
| Resistance Level | $13.74 | $19.06 |
| Average True Range (ATR) | 0.26 | 1.33 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 53.33 | 48.39 |
Price Performance
Historical ComparisonAbout BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.